Register

Site

As above

Content

Intended for use only by healthcare professionals and researchers, the Register will provide a comprehensive record of all phase II-IV studies conducted on the company’s newly registered medicines.

So far the register contains details on the following compounds:

Abacavir Sulfate (14 studies)
Amprenavir (19)
Lamivudine or 3TC (31)
Salmeterol Xinafoate PLUS Fluticasone Propionate
combination product (=Seretide) (11)
Zanamivir (7).
The record of each study provides further information, including: compound, study ID, title, status, phase, number of patients, indication, trial design, endpoint/outcome measure, treatments, participating countries, and publication status.

Other information available

The site also contains a What’s New section. There are links back to the Glaxo Wellcome corporate home page and the Glaxo Wellcome R&D Science home page, but no external links.

Access

Pre-registration required. ID number and password are issued within five working days to healthcare professionals and researchers only.

Comments

The Study Search facility allows searching on the following criteria: compound, indication, country, and study endpoint.

Each study record contains a ‘raise queries’ button which is forwarded to a representative “for immediate action”.

This Clinical Trials Register was re-launched on October 1; it is updated immediately following new major approvals (EU or US approval) and at least annually for existing compounds.

Register

Site

As above

Content

Intended for use only by healthcare professionals and researchers, the Register will provide a comprehensive record of all phase II-IV studies conducted on the company’s newly registered medicines. So far the register contains details on the following compounds: Abacavir Sulfate (14 studies)Amprenavir (19)Lamivudine or 3TC (31)Salmeterol Xinafoate PLUS Fluticasone Propionatecombination product (=Seretide) (11)Zanamivir (7).The record of each study provides further information, including: compound, study ID, title, status, phase, number of patients, indication, trial design, endpoint/outcome measure, treatments, participating countries, and publication status.

Other information available

The site also contains a What’s New section. There are links back to the Glaxo Wellcome corporate home page and the Glaxo Wellcome R&D Science home page, but no external links.

Access

Pre-registration required. ID number and password are issued within five working days to healthcare professionals and researchers only.

Comments

The Study Search facility allows searching on the following criteria: compound, indication, country, and study endpoint. Each study record contains a ‘raise queries’ button which is forwarded to a representative “for immediate action”. This Clinical Trials Register was re-launched on October 1; it is updated immediately following new major approvals (EU or US approval) and at least annually for existing compounds.